Dawson James reiterated their neutral rating on shares of CEL-SCI Co. (NYSEMKT:CVM) in a research report report published on Monday, October 16th.
Separately, ValuEngine raised shares of CEL-SCI from a strong sell rating to a sell rating in a report on Monday, August 14th.
CEL-SCI (NYSEMKT CVM) opened at 1.68 on Monday. The stock’s market capitalization is $15.68 million. CEL-SCI has a 52 week low of $0.06 and a 52 week high of $3.69. The company has a 50-day moving average of $1.73 and a 200-day moving average of $1.37.
ILLEGAL ACTIVITY WARNING: “CEL-SCI Co. (NYSEMKT:CVM) Earns “Neutral” Rating from Dawson James” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://www.dispatchtribunal.com/2017/10/27/cel-sci-co-cvm-given-neutral-rating-at-dawson-james.html.
In other CEL-SCI news, insider Eyal Talor sold 14,019 shares of the stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $2.61, for a total transaction of $36,589.59. Following the transaction, the insider now owns 131,312 shares of the company’s stock, valued at $342,724.32. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
CEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company is focused on activating the immune system to fight cancer and infectious diseases. It operates through the segment of research and development of certain drugs and vaccines.
Receive News & Ratings for CEL-SCI Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI Co. and related companies with MarketBeat.com's FREE daily email newsletter.